Anika Therapeutics Inc (ANIK) Q3 2026 Earnings Call Highlights: Revenue Growth and Margin Gains ...
Anika Therapeutics Inc (ANIK) posted 10% revenue growth and record commercial channel sales in Q3 2026, but lowered commercial guidance and faces FDA setbacks on its Hyalafast PMA. Related Stocks: ANIK ,